UBS Group AG Acquires 100,160 Shares of Harrow, Inc. $HROW

UBS Group AG increased its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 82.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 222,362 shares of the company’s stock after buying an additional 100,160 shares during the quarter. UBS Group AG owned 0.60% of Harrow worth $10,896,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of HROW. Royal Bank of Canada lifted its position in shares of Harrow by 102.5% during the 1st quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock worth $261,000 after buying an additional 4,967 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Harrow by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock worth $483,000 after buying an additional 790 shares during the last quarter. Strs Ohio bought a new stake in shares of Harrow during the 1st quarter worth $149,000. Legal & General Group Plc lifted its position in shares of Harrow by 12.4% during the 2nd quarter. Legal & General Group Plc now owns 30,753 shares of the company’s stock worth $939,000 after buying an additional 3,384 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Harrow by 9.3% during the 2nd quarter. Rhumbline Advisers now owns 46,969 shares of the company’s stock worth $1,434,000 after buying an additional 3,994 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HROW has been the subject of a number of recent research reports. B. Riley Financial reaffirmed a “buy” rating and issued a $65.00 target price (down from $74.00) on shares of Harrow in a report on Tuesday, April 7th. BTIG Research reaffirmed a “buy” rating and issued a $63.00 target price on shares of Harrow in a report on Tuesday. William Blair reaffirmed an “outperform” rating on shares of Harrow in a report on Tuesday, March 3rd. Nomura cut Harrow to a “neutral” rating in a report on Wednesday, March 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Harrow in a report on Thursday, March 19th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Harrow has a consensus rating of “Moderate Buy” and an average price target of $69.43.

Harrow Price Performance

Shares of HROW opened at $31.21 on Friday. Harrow, Inc. has a 12-month low of $25.21 and a 12-month high of $54.85. The business has a 50-day simple moving average of $36.51 and a two-hundred day simple moving average of $42.13. The company has a quick ratio of 2.06, a current ratio of 2.48 and a debt-to-equity ratio of 10.30. The stock has a market cap of $1.16 billion, a PE ratio of -76.12 and a beta of 0.34.

Harrow (NASDAQ:HROW) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.31). The company had revenue of $44.20 million during the quarter, compared to analyst estimates of $52.43 million. Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. During the same period in the previous year, the company posted ($0.38) EPS. Analysts anticipate that Harrow, Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Buying and Selling at Harrow

In related news, CFO Andrew R. Boll purchased 3,500 shares of the firm’s stock in a transaction dated Thursday, May 14th. The stock was bought at an average price of $29.90 per share, with a total value of $104,650.00. Following the completion of the purchase, the chief financial officer owned 814,679 shares in the company, valued at approximately $24,358,902.10. This represents a 0.43% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 12.80% of the company’s stock.

Harrow Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.